Selecta Biosciences, Inc. - SELB STOCK NEWS

Cartesian Therapeutics, Inc. (NASDAQ: RNAC) announced positive twelve-month follow-up data from its Phase 2a trial of Descartes-08 in patients with generalized myasthenia gravis (MG), a chronic autoimmune disorder. Descartes-08, an autologous anti-B-cell maturation antigen (BCMA) mRNA CAR-T, showed durable depletion of autoantibodies and clinically meaningful improvements in MG severity scores without the need for lymphodepleting chemotherapy. The manuscript titled, 'Twelve-Month Follow-Up of Patients With Generalized Myasthenia Gravis Receiving BCMA-Directed mRNA Cell Therapy,' has been submitted for peer-review and can be accessed on the online preprint server, medRxiv. Topline data from a Phase 2b placebo-controlled study is expected in mid-2024.

Selecta Biosciences, Inc. (NASDAQ: SELB) announced a merger with Cartesian Therapeutics, Inc., creating a publicly traded company pioneering RNA cell therapy for autoimmune diseases. The merger brings a pro forma cash balance of over $110 million, including $60.25 million from private financing, supporting the development of Descartes-08, a potential first-in-class RNA-engineered chimeric antigen receptor T-cell therapy for myasthenia gravis (MG), and additional RNA cell therapy programs. The combined company is expected to have multiple near-term catalysts, including data from the Phase 2b study of Descartes-08 in MG in mid-2024, and initiation of studies in additional autoimmune indications.

Selecta Biosciences has entered into an agreement with Swedish Orphan Biovitrum AB (Sobi) to transition the manufacturing and development rights of ImmTOR for SEL-212. Sobi will assume responsibility for manufacturing and commercial supply starting November 6, 2023. The Biologics License Application (BLA) submission for SEL-212 is on track for the first half of 2024. Selecta employees supporting ImmTOR manufacturing and clinical development activities for SEL-212 are expected to become Sobi employees. Selecta is eligible to receive up to $615.0 million in milestone payments and royalties on net sales of SEL-212.

Selecta Biosciences reports Q2 2023 financial results and provides business update

Selecta Biosciences reports positive Phase 3 data, plans capital prioritization initiative to extend cash runway

Cellarity, a life sciences company, has announced several key leadership appointments to enhance its innovative drug discovery platform. John Leaman, M.D., M.B.A., joins as Chief Financial Officer, bringing extensive experience from Impel Pharmaceuticals, Selecta Biosciences, and Medgenics. Cameron Trenor, M.D., is appointed as Vice President and Head of Translational Medicine, with a strong background in hematology drug development. Anjali Kumar, Ph.D., takes on the role of Vice President, Head of Business Development, previously leading innovation at Johnson & Johnson. Additionally, Parul Doshi, M.B.A., has been promoted to Chief Data Officer. These changes aim to accelerate Cellarity's progress towards its clinical pipeline, leveraging its proprietary AI platform to create novel drug candidates for complex diseases.

On March 21, 2023, Selecta Biosciences (NASDAQ: SELB) reported positive topline results from its Phase 3 DISSOLVE I and II trials for SEL-212, an investigational treatment for chronic refractory gout. In DISSOLVE I, 56% of patients achieved a response at a high dose, significantly outperforming the placebo rate of 4%. DISSOLVE II showed a 47% response rate at the same dosage compared to 12% for placebo. The treatment demonstrated a 69% reduction in serum urate levels and maintained a favorable safety profile, with only 3.4% of patients experiencing infusion reactions. The company aims to file for U.S. marketing approval in the first half of 2024.